Modification of Antitumor Immunity and Tumor Microenvironment by Resveratrol in Mouse Renal Tumor Model

被引:0
作者
Liang Chen
Sixing Yang
Wenbiao Liao
Yunhe Xiong
机构
[1] Renmin Hospital of Wuhan University,Department of Urology
来源
Cell Biochemistry and Biophysics | 2015年 / 72卷
关键词
Resveratrol; Renal cell carcinoma; CD8; T cells; Tumor microenvironment; Fas; Fas ligand; Cytokine;
D O I
暂无
中图分类号
学科分类号
摘要
Renal cell carcinoma (RCC) microenvironment plays critical roles in antitumor immune response. Resveratrol exhibits a direct antitumor effect in various tumor models. However, the immunomodulatory effect of resveratrol on RCC microenvironment is unknown. In this study, we found that administration of low dose of resveratrol inhibits Renca tumor growth and its inhibition effect depends on CD8+ T cells. Moreover, the proportion of regulatory T cells is decreased, while the proportion of myeloid-derived suppressor cells does not alter after resveratrol treatment. More importantly, massive amount of activated CD8+ T cells accumulates in tumor microenvironment in the resveratrol-treated group and shows increased cytotoxicity, as indicated by a higher expression of Fas ligand. We also found that resveratrol switches the expression of T-helper (Th) 2 cytokines such as interleukin (IL)-6 and IL-10 to Th 1 cytokines with dominance of interferon (IFN)-γ, which increases the expression of Fas in Renca cells. Furthermore, we found resveratrol down-regulates angiogenesis along with decreased level of vascular endothelial growth factor in tumor microenvironment. Our results strongly suggest that resveratrol might be used for RCC immunotherapy through modulating tumor microenvironment.
引用
收藏
页码:617 / 625
页数:8
相关论文
共 88 条
[1]  
Gupta K(2008)Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review Cancer Treatment Reviews 34 193-205
[2]  
Miller JD(1987)A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone The New England Journal of Medicine 316 889-897
[3]  
Li JZ(2011)Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence The Oncologist 16 14-22
[4]  
Russell MW(2012)Emerging immunotherapies for renal cell carcinoma Annals of oncology 23 viii35-viii40
[5]  
Charbonneau C(2007)Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma Acta Medica 50 207-212
[6]  
Rosenberg SA(2013)Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Cancer Journal 19 353-364
[7]  
Lotze MT(2008)Cytokines and their relationship to the symptoms and outcome of cancer Nature Reviews Cancer 8 887-899
[8]  
Muul LM(2006)Interferons, immunity and cancer immunoediting Nature Reviews Immunology 6 836-848
[9]  
Hutson TE(2000)IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells Journal of Immunology 164 231-239
[10]  
Escudier B(2011)Chemosensitization of tumors by resveratrol Annals of the New York Academy of Sciences 1215 150-160